Showing results (31-40 of 53) with videos related to

Sort By:
Pageof 6
Antimicrobial Agents and Chemotherapy|August 22, 2000
Use of saliva specimens for monitoring indinavir therapy in human immunodeficiency virus-infected patientsU Wintergerst, M Kurowski, B Rolinski, et al.
Injury Epidemiology|July 3, 2023
Impact of standardization on racial and socioeconomic disparities in non-accidental trauma evaluations in infants in a pediatric emergency departmentLaura Even Elliott, Michael A Gittelman, Eileen M Kurowski, et al.
The Journal of Antimicrobial Chemotherapy|June 29, 2005
Impact of rosiglitazone treatment on the bioavailability of antiretroviral compounds in HIV-positive patientsM Oette, M Kurowski, T Feldt, et al.
European Journal of Medical Research|July 6, 2006
Pharmacokinetics and tolerability of a combination of indinavir, lopinavir and ritonavir in multiply pretreated HIV-1 infected adultsNils von Hentig, A Müller, C Rottmann, et al.
International Journal of STD & AIDS|March 3, 2007
Dose reduction effective in alleviating symptoms of saquinavir toxicityC Stephan, A Carlebach, C Rottmann, et al.
AIDS (London, England)|June 17, 2004
Long-term pharmacokinetics of amprenavir in combination with delavirdine in HIV-infected childrenC Engelhorn, F Hoffmann, M Kurowski, et al.
Mediators of Inflammation|June 28, 2008
Increased responsiveness to toll-like receptor 4 stimulation in peripheral blood mononuclear cells from patients with recent onset rheumatoid arthritisM L Kowalski, A Wolska, J Grzegorczyk, et al.
HIV Medicine|January 21, 2004
A prospective, controlled study assessing the effect of lopinavir on amprenavir concentrations boosted by ritonavirS Mauss, S Scholten, E Wolf, et al.
European Journal of Medical Research|August 2, 2007
Differences of nine drug resistance interpretation systems in predicting short-term therapy outcomes of treatment-experienced HIV-1 infected patients: a retrospective observational cohort studyM Helm, H Walter, R Ehret, et al.
HIV Medicine|March 4, 2014
Immune activation despite suppressive highly active antiretroviral therapy is associated with higher risk of viral blips in HIV-1-infected individualsA Zoufaly, J G Kiepe, S Hertling, et al.
Pageof 6